March 18 (Reuters) - Aclaris Therapeutics Inc ACRS.O:
ACLARIS THERAPEUTICS COMPLETES ENROLLMENT IN PHASE 2 TRIAL OF BOSAKITUG (ATI-045) IN ATOPIC DERMATITIS
ACLARIS THERAPEUTICS INC - TOP LINE RESULTS FROM PHASE 2 TRIAL EXPECTED IN Q4 2026
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.